Not applicableNot Yet RecruitingNCT07618546
What this trial is testing
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Who this might be right for
HCC - Hepatocellular Carcinoma
Henan Cancer Hospital 208